Blood:免疫调节剂(IMiDs)通过促进Ikaros/Aiolos降解来上调CD38,进而增强达雷木单抗介导的骨髓瘤细胞杀伤

2018-09-20 MedSci MedSci原创

中心点:Ikaros和Aiolos失活可再现IMiDs在MM中的细胞内在作用以及转录变化。Ikaros或Aiolos缺失可上调干扰素刺激基因,包括CD38。摘要:近期有研究表明免疫调节药物(IMiDs)可促进转录因子Ikaros和Aiolos降解。但是,Ikaros和Aiolos缺失为何可导致多发性骨髓瘤(MM)细胞死亡尚不明确。Pasquale L. Fedele等研究人员采用CRISPR-Ca

中心点:

Ikaros和Aiolos失活可再现IMiDs在MM中的细胞内在作用以及转录变化。

Ikaros或Aiolos缺失可上调干扰素刺激基因,包括CD38。

摘要:

近期有研究表明免疫调节药物(IMiDs)可促进转录因子Ikaros和Aiolos降解。但是,Ikaros和Aiolos缺失为何可导致多发性骨髓瘤(MM)细胞死亡尚不明确。

Pasquale L. Fedele等研究人员采用CRISPR-Case9基因编辑,建立敲除IKZF1/Ikaros和IKZF3/Aiolos敲除的人类MM细胞系,进一步研究其下游基因的调控网络。结果显示任一种失活均可再现IMiDs的细胞内在作用,导致细胞周期阻滞和诱导细胞凋亡。

此外,转录谱分析显示Ikaros或Aiolos失活与来那度胺治疗的效果有显著的重叠。这些效果并不依赖IRF4-MYC轴的降低,因为在细胞死亡过程中两种蛋白均无持续降低,加上过表达任一种细胞因子都不能恢复Ikaros丢失。

重要的是,Ikaros和Aiolos抑制干扰素刺激基因(ISGs,包括CD38)的表达,其缺失可激活干扰素样反应,导致MM细胞死亡。Ikaros/Aiolos通过与核小体重构和脱乙酰酶复合物相互作用,抑制MM细胞的CD38表达。IMiD诱导Ikaros缺失或干扰素治疗均导致MM细胞表面的CD38表达增加,从而启动达雷木单抗诱导的NK细胞介导的抗体依赖性的细胞毒性作用。

综上所述,本研究进一步揭示了IMiDs的作用机制,为联合抗CD38单克隆抗体治疗提供机制理论。


原始出处:

Pasquale L. Fedele,et al. IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38. Blood  2018  :blood-2018-05-850727;  doi: https://doi.org/10.1182/blood-2018-05-850727

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2019-05-31 yangshch
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2019-01-24 jxrzshh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-10-08 xuqianhua
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-28 1e145228m78(暂无匿称)

    学习了,谢谢作者分享/

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-22 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-20 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1779627, encodeId=c2cc1e7962746, content=<a href='/topic/show?id=9b5a218389' target=_blank style='color:#2F92EE;'>#Aiolos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2183, encryptionId=9b5a218389, topicName=Aiolos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri May 31 00:20:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694061, encodeId=e17c1694061ba, content=<a href='/topic/show?id=8fa99e62c5' target=_blank style='color:#2F92EE;'>#IMiDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9762, encryptionId=8fa99e62c5, topicName=IMiDs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f029545346, createdName=jxrzshh, createdTime=Thu Jan 24 20:20:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744430, encodeId=4f8c1e44430cf, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Mon Oct 08 10:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347017, encodeId=939f34e0170a, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Sep 28 05:15:39 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364389, encodeId=41a91364389d0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499925, encodeId=5162149992594, content=<a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93969, encryptionId=9eb09396903, topicName=达雷木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ce9392241, createdName=xuyu, createdTime=Sat Sep 22 00:20:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345908, encodeId=22903459080a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 20 23:46:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345801, encodeId=1ebd345801c2, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Thu Sep 20 09:43:39 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-20 lietome24

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

相关资讯

不符合自体干细胞移植的多发性骨髓瘤患者的福音

强生公司的Janssen制药公司于2018年7月28日宣布,欧洲药品管理局(EMA)的人用药品委员会(CHMP)建议扩大Darzalex®(daratumumab)的现有上市许可,daratumumab联合硼替佐米、美法仑和泼尼松前线(初始)治疗不符合自体干细胞移植(ASCT)要求的多发性骨髓瘤患者。

Blood:研究人员发现可鉴别多发性骨髓瘤患者对哪种治疗方案更敏感的基因印迹

中心点:研究人员推断出一种7基因印迹,可鉴别对硼替佐米或以来那度胺为基础的疗法更敏感的骨髓瘤患者。根据印迹治疗的效果不次于采用硼替佐米、来那度胺和地塞米松联合治疗。摘要:改善多发性骨髓瘤患者的预后不仅要开发新的疗法,更要更好的应用现有的治疗措施。Michael A. Chapman等人采用II期PADIMAC(以硼替佐米、阿霉素和地塞米松[PAD]联合治疗未进行过治疗的多发性骨髓瘤患者:延期ASC

JAMA Oncol:骨髓瘤维持治疗,哪个方案更优?

目前已有多项研究探索了多发性骨髓瘤(MM)的维持治疗。尽管研究结果提示维持治有一定疗效,但尚无证据显示何种维持治疗方案更优。近期,发布于JAMA Oncology杂志的一项荟萃分析,探讨了各个维持治疗方案对比无维持治疗或安慰剂维持的疗效,并在特定人群中进行了疗效对比。

CLIN CANCER RES:通过靶向白血病抗原PR1的免疫疗法治疗多发性骨髓瘤

PR1是来源于中性粒细胞弹性蛋白酶(NE)和蛋白酶3(P3)的人HLA-A2肽。既往的研究表明PR1在实体肿瘤,白血病和抗原呈递细胞(包括B细胞)中交叉表达。实体肿瘤PR1交叉表达使其对靶向PR1的免疫治疗敏感。多发性骨髓瘤来源于B细胞,CLIN CANCER RES近期发表了一篇文章,研究多发性骨髓瘤是否也交叉表达PR1以及是否可以利用PR1免疫疗法进行靶向治疗。

2018 EMN建议:多发性骨髓瘤的诊断和监测

2018年8月,欧洲骨髓瘤网络(EMN)发布了多发性骨髓瘤的诊断和监测建议,多发性骨髓瘤的诊断充满调整,即使是经验丰富的临床医生,在骨髓瘤最终确诊前仍然需要多学科协作。EMN更新了骨髓瘤鉴别诊断建议。

Blood:ADAR1过度编辑多发性骨髓瘤的转录本,促进病程进展,是预后不良的标志之一

迄今为止,多发性骨髓瘤(MM)仍是一种无法治愈的疾病,目前在MM患者中广泛发现DNA该变;但是,DNA改变不能完全解释MM的所有生物和分子异常。今年来,已发现RNA水平异常与癌症的生物学特性具有相关性。ADAR1介导的A-I编辑是人类生理的一个重要的转录后修饰机制;其异常在MM中的生物学意义,尤其是在整体水平,尚未得到阐明。Phaik Ju Teoh等人尝试阐明RNA编辑的生物学应用,以及其是对M